EDITORIAL

Rapamycin eluting stent: the onset of a new era in interventional cardiology

P W Serruys¹, E Regar¹, A J Carter²

¹ Department of Cardiology, Thoraxcentre, Erasmus Medical Centre, Rotterdam, The Netherlands
² Stanford University Medical Center, Stanford, California, USA

Correspondence to:
Correspondence to:
Professor P W Serruys, Interventional Department, Thoraxcentre, Bd. 408, University Hospital Dijkzigt, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands;
serruys@card.azr.nl

---

Drug eluting stents represent one of the fastest growing fields in interventional cardiology today.

---

Keywords: rapamycin eluting stents; stents; interventional cardiology

Abbreviations: FR, fast release; IL, interleukin; IVUS, intravascular ultrasound; mTOR, mammalian target of rapamycin; PBMA, polybutylmethacrylate; PCNA, proliferating cell nuclear antigen; PEVA, polyethylenevinylacetate; RAVEL, randomised study with sirolimus coated BX Velocity balloon expandable stent in the treatment of patients with de novo native coronary lesions; SR, slow release; VEGF, vascular endothelial growth factor

At the congress of the European Society of Cardiology in Amsterdam in 2000, I (PWS) was asked to give the Andreas Gruentzig Lecture. In the week preceding the lecture, we re-angiographied patients 32 and 33 of the initial cohort of patients who had received a rapamycin eluting stent in Sao Paulo and in Rotterdam. Scrutinising the 4–6 month angiographic and ultrasonic results of these patients, I became overwhelmingly convinced that we were the privileged witnesses of a new phenomenon: the almost complete abolition of intra-stent neointimal proliferation. Colleagues, invasive and non-invasive cardiologists, old friends, and financial analysts were surprised by the unusual "excess of enthusiasm" coming from somebody who has built over the years a reputation as a critical assessor, never one to be carried away by the hype of a new wave in interventional cardiology. In the history of this field I have recognised (and "got excited" by, as . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Zhao, M. Y., Auerbach, A., D'Costa, A. M., Rapoport, A. P., Burger, A. M., Sausville, E. A., Stass, S. A., Jiang, F., Sands, A. M., Aguilera, N., Zhao, X. F. (2009). Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy. Clin. Cancer Res. 15: 1708-1720 [Abstract] [Full Text]  
• Cyrus, T., Zhang, H., Allen, J. S., Williams, T. A., Hu, G., Caruthers, S. D., Wickline, S. A., Lanza, G. M. (2008). Intramural Delivery of Rapamycin With {alpha}v{beta}3-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury. Arterioscler. Thromb. Vasc. Bio. 28: 820-826 [Abstract] [Full Text]  
• Hahn, M., Li, W., Yu, C., Rahmani, M., Dent, P., Grant, S. (2005). Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Molecular Cancer Therapeutics 4: 457-470 [Abstract] [Full Text]  
• Schwartz, R. S., Edelman, E. R., For the Consensus Committee, , Carter, A., Chronos, N. A., Rogers, C., Robinson, K. A., Waksman, R., Machan, L., Weinberger, J., Wilensky, R. L., Goode, J. L., Hottenstein, O.D., Zuckerman, B. D., Virmani, R. (2004). Preclinical Evaluation of Drug-Eluting Stents for Peripheral Applications: Recommendations From an Expert Consensus Group. Circulation 110: 2498-2505 [Full Text]  
• Degertekin, M., Regar, E., Tanabe, K., Smits, P. C., van der Giessen, W. J., Carlier, S. G., de Feyter, P., Vos, J., Foley, D. P., Ligthart, J. M. R., Popma, J. J., Serruys, P. W. (2003). Sirolimus-eluting stent for treatment of complex in-stent restenosis: The first clinical experience. J Am Coll Cardiol 41: 184-189 [Abstract] [Full Text]  
• Schwartz, R. S., Edelman, E. R., Carter, A., Chronos, N., Rogers, C., Robinson, K. A., Waksman, R., Weinberger, J., Wilensky, R. L., Jensen, D. N., Zuckerman, B. D., Virmani, R., For the Consensus Committee:, (2002). Drug-Eluting Stents in Preclinical Studies: Recommended Evaluation From a Consensus Group. Circulation 106: 1867-1873 [Full Text]  
• Degertekin, M., Serruys, P. W., Foley, D. P., Tanabe, K., Regar, E., Vos, J., Smits, P. C., van der Giessen, W. J., van den Brand, M., de Feyter, P., Popma, J. J. (2002). Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up. Circulation 106: 1610-1613 [Abstract] [Full Text]